Dina Bassiouny
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dina Bassiouny has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Parra-Herran
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States
2 shared publications - Danielle Vicus
Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of Toronto, Toronto, ON M5G 1E2, Canada
2 shared publications Liat Hogen
Division of Gynecologic Oncology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Division of Gynecologic Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Department of Obstetrics and Gynecology, University of Toronto, Canada
2 shared publicationsLilian T. Gien
Division of Gynecologic Oncology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Department of Obstetrics and Gynecology, University of Toronto, Canada
2 shared publicationsMatthew Cesari
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
2 shared publicationsNadia Ismiil
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
2 shared publications
Latest Publications
- Open Access
AI Generated Stromal Biomarkers for DCIS Reccurence Prediction
Background: Although DCIS has a relatively low recurrence rate, many patients still receive adjuvant radiotherapy or endocrine therapy, raising concerns about overtreatment. Reliable biomarkers are therefore needed to predict an individual patient’s risk and guide treatment decisions. Recent studies suggest that the composition of the tumour-associated stroma (TAS) affects progression and outcome, highlighting TAS-derived biomarkers as promising candidates for further investigation. Methods: We trained AI models for cell and tumour segmentation using whole slide digital pathology images acquired as part of a retrospective cohort study. We investigated the effects of cell density within both the tumour and the TAS to determine how they correlated with recurrence in the ipsilateral breast. Results: We found that the concentration of DCIS lesions on the slide and the density of mitotic figures inside the TAS region were significantly associated with recurrence risk. Additionally, we found some predictive value in the lymphocyte and red blood cell densities in different tumour regions. Stromal composition was shown to associate with recurrence risk, and density-based biomarkers were identified and used to cluster patients into phenotypes with significantly different risk profiles. Conclusion: Our findings highlight the prognostic relevance of stromal composition in DCIS, and we identify novel density-based biomarkers that can be used to identify patients who are more likely to experience a local recurrence after breast-conserving surgery alone. These results may aid in developing future risk-stratification tools for breast cancer patients, thereby reducing overtreatment and improving patient care.
Open AccessAI Generated Stromal Biomarkers for DCIS Reccurence Prediction
Background: Although DCIS has a relatively low recurrence rate, many patients still receive adjuvant radiotherapy or endocrine therapy, raising concerns about overtreatment. Reliable biomarkers are therefore needed to predict an individual patient’s risk and guide treatment decisions. Recent studies suggest that the composition of the tumour-associated stroma (TAS) affects progression and outcome, highlighting TAS-derived biomarkers as promising candidates for further investigation. Methods: We trained AI models for cell and tumour segmentation using whole slide digital pathology images acquired as part of a retrospective cohort study. We investigated the effects of cell density within both the tumour and the TAS to determine how they correlated with recurrence in the ipsilateral breast. Results: We found that the concentration of DCIS lesions on the slide and the density of mitotic figures inside the TAS region were significantly associated with recurrence risk. Additionally, we found some predictive value in the lymphocyte and red blood cell densities in different tumour regions. Stromal composition was shown to associate with recurrence risk, and density-based biomarkers were identified and used to cluster patients into phenotypes with significantly different risk profiles. Conclusion: Our findings highlight the prognostic relevance of stromal composition in DCIS, and we identify novel density-based biomarkers that can be used to identify patients who are more likely to experience a local recurrence after breast-conserving surgery alone. These results may aid in developing future risk-stratification tools for breast cancer patients, thereby reducing overtreatment and improving patient care.
- 16 January 2018
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 26 (4) , 306-317
Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma
The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.
- 16 January 2018
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 26 (4) , 306-317
Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma
The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.
- Open Access
- 1 December 2017
- Published by Elsevier in Laboratory Investigation
- Vol. 30 (12) , 1748-1759
Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups
- 1 December 2017
- Published by Elsevier in Laboratory Investigation
- Vol. 30 (12) , 1748-1759
Open AccessMolecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups
- 1 October 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (1) , 54-60
Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?
- 1 October 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (1) , 54-60
Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?
- 1 November 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (2) , 258-263
The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma
- 1 November 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (2) , 258-263
The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma